Sarcoidosis Induced by Tocilizumab: A Paradoxical Event?

To the Editor: Tocilizumab (TCZ) is a monoclonal antibody against the interleukin 6 (IL-6) receptor, used in the treatment of rheumatoid arthritis (RA). We describe a case of onset of sarcoidosis under TCZ therapy in a patient with RA. A 40-year-old woman of North African origin had RA for 12 years. Rheumatoid factor and anticitrullinated antibody were negative. Erosions were absent. Nevertheless, she fulfilled the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) RA classification criteria (7/10). She was refractory to sulfasalazine and then to methotrexate (MTX). Etanercept was introduced in 2008 and stopped in 2010 because of secondary loss of efficacy. TCZ was initiated in April 2010. The response was good, with the 28-joint Disease Activity Score (DAS28) 0.5 and Health Assessment Questionnaire … Address correspondence to Dr. Cohen, Hopital Lapeyronie, Unite d’Immuno-Rhumatologie, 191 Avenue du Doyen Gaston Giraud, Montpellier 34295, France. E-mail: jd-cohen{at}chu-montpellier.fr

[1]  E. Ito,et al.  Tocilizumab-induced immune complex glomerulonephritis in a patient with rheumatoid arthritis. , 2013, Rheumatology.

[2]  P. Jolliet,et al.  Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect? , 2012, Clinical and experimental rheumatology.

[3]  C. Prati,et al.  Psoriasis Onset with Tocilizumab Treatment for Rheumatoid Arthritis , 2012, The Journal of Rheumatology.

[4]  C. Prati,et al.  Onset of Inflammatory Eye Disease Under Tocilizumab Treatment for Rheumatologic Conditions: a Paradoxical Effect? , 2011, The Journal of Rheumatology.

[5]  Philip R. Cohen,et al.  TNF alpha antagonist‐induced lupus‐like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists , 2011, International journal of dermatology.

[6]  S. Pavy,et al.  Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. , 2009, Rheumatology.

[7]  M. Khamashta,et al.  Vasculitis induced by tumor necrosis factor-targeted therapies , 2008, Current rheumatology reports.

[8]  S. Sone,et al.  Sarcoidosis associated with acute renal failure and increased levels of interleukin-6 in urine. , 1998, Internal medicine.

[9]  M. Yamakido,et al.  Increased expression of tumor necrosis factor-alpha, interleukin-6, platelet-derived growth factor-B and granulocyte-macrophage colony-stimulating factor mRNA in cells of bronchoalveolar lavage fluids from patients with sarcoidosis. , 1996, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[10]  G. Hoser,et al.  Th1/Th2/Th17‑related cytokines in the bronchoalveolar lavage fluid of patients with sarcoidosis: association with smoking. , 2012, Polskie Archiwum Medycyny Wewnetrznej.